Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Global and targeted serum metabolic profiling of colorectal cancer progression

Global and targeted serum metabolic profiling of colorectal cancer progression INTRODUCTIONColorectal cancer (CRC) is one of the most prevalent and deadly types of cancer worldwide and is a major cause of human morbidity and mortality. As the third most common type of cancer in the United States according to the American Cancer Society, CRC has been estimated to be responsible for more than 136,000 new cases and 50,000 deaths in 2015. Several preventive screening and detection methods, including the fecal occult blood test, the fecal immunochemical test, colonoscopy, sigmoidoscopy, and a family history–based risk assessment, have been suggested for CRC.The development of improved and robust biomarkers to enable the screening, surveillance, and early detection of CRC continues to be a challenge. Patients with colorectal adenoma polyps (PLPs) are at higher risk for developing colon cancer; however, noninvasive methods for identifying these patients with high sensitivity and specificity are not clinically available. Studies describing molecular phenotypes of patients with CRC and PLPs can improve the understanding of the pathophysiology of CRC and offer strategies for monitoring the population at risk for CRC.Serum metabolites are emerging as promising minimally invasive biomarkers for the early detection and prognostication of cancers. Metabolomics, one of the omic sciences in systems biology, is the global http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Wiley

Global and targeted serum metabolic profiling of colorectal cancer progression

Download PDF
9 pages

Loading next page...
 
/lp/wiley/global-and-targeted-serum-metabolic-profiling-of-colorectal-cancer-C1oPevVVxy

References (37)

Publisher
Wiley
Copyright
"© 2017 American Cancer Society"
ISSN
0008-543X
eISSN
1097-0142
DOI
10.1002/cncr.30829
pmid
28640361
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONColorectal cancer (CRC) is one of the most prevalent and deadly types of cancer worldwide and is a major cause of human morbidity and mortality. As the third most common type of cancer in the United States according to the American Cancer Society, CRC has been estimated to be responsible for more than 136,000 new cases and 50,000 deaths in 2015. Several preventive screening and detection methods, including the fecal occult blood test, the fecal immunochemical test, colonoscopy, sigmoidoscopy, and a family history–based risk assessment, have been suggested for CRC.The development of improved and robust biomarkers to enable the screening, surveillance, and early detection of CRC continues to be a challenge. Patients with colorectal adenoma polyps (PLPs) are at higher risk for developing colon cancer; however, noninvasive methods for identifying these patients with high sensitivity and specificity are not clinically available. Studies describing molecular phenotypes of patients with CRC and PLPs can improve the understanding of the pathophysiology of CRC and offer strategies for monitoring the population at risk for CRC.Serum metabolites are emerging as promising minimally invasive biomarkers for the early detection and prognostication of cancers. Metabolomics, one of the omic sciences in systems biology, is the global

Journal

Cancer – Wiley

Published: Mar 15, 2018

Keywords: ; ; ; ;

There are no references for this article.